Biological Activity:
Pramipexole (Mirapex) is a partial/full D2S, D2L, D3, D4 receptor agonist with a Ki of 3.9, 2.2, 0.5 and 5.1 nM for D2S, D2L, D3, D4 receptor, respectively. Pramipexole (Mirapex) also possesses low/insignificant affinity (500-10,000 nM) for the 5-HT1A, 5-HT1B, 5-HT1D, and α2-adrenergic receptors. Pramipexole (Mirapex) has negligible affinity (>10,000 nM) for the D1, D5, 5-HT2, α1-adrenergic, β-adrenergic, H1, and mACh receptors. Pramipexole (Mirapex) is a non-ergoline dopamine agonist revealed for treating early-stage Parkinson’s disease (PD) and restless legs syndrome (RLS). [1][2][3]References on Pramipexole (Mirapex)[1] http://en.wikipedia.org/wiki/Pramipexole, , [2] Clin Ther., 2006 Aug, 28(8):1065-78.[3] J Pharmacol Exp Ther., 2002 Nov, 303(2):805-14.